Article
Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir Among Children Living with HIV Failing on First-Line Antiretroviral Therapy in Uganda.
Journal of acquired immune deficiency syndromes (1999) - 1 Feb 2026
Magongo Eleanor N, Hast Marisa, Nabitaka Vennie, Nakanwagi Miriam, Twinomujjuni Evarist, Dowling Stephanie, Senyama George, Nzano Brian, Alwano Mary, Nakaweesi Jane, Nazziwa Esther, Namayanja Grace, Nkolo Esther, Ayitewala Alisen, Hackett Stephanie
Abstract excerpt
BACKGROUND: Introduction of pediatric-friendly dolutegravir (DTG) formulations to treat children living with HIV (CLHIV) has presented new opportunities to improve viral suppression; however, there are limited data on emerging patterns of HIV drug resistance (HIVDR) in this population. METHODS: We identified CLHIV aged 0-15 years experiencing virologic failure on first-line antiretroviral therapy in Uganda...
Topics
Join the communities discussing this publication.
